Halozyme Therapeutics Inc (HALO)

Return on assets (ROA)

		Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net income	US$ in thousands	444,091	281,594	202,129	402,710	129,085
Total assets	US$ in thousands	2,063,480	1,733,270	1,841,510	1,104,430	579,924
ROA		21.52%	16.25%	10.98%	36.46%	22.26%

December 31, 2024 calculation

ROA = Net income ÷ Total assets
= $444,091K ÷ $2,063,480K
= 21.52%

Halozyme Therapeutics Inc's return on assets (ROA) demonstrates a fluctuating trend over the years. In December 2020, the ROA was reported at 22.26%, showing a strong performance in generating profit relative to its total assets. The following year, in December 2021, the ROA increased significantly to 36.46%, indicating improved efficiency in utilizing assets to generate earnings.

However, in December 2022, the ROA decreased to 10.98%, suggesting a decline in the company's ability to generate profit from its assets. The trend reversed in December 2023 with an ROA of 16.25%, showing a partial recovery in asset utilization efficiency. By December 2024, the ROA improved further to 21.52%, indicating a stronger performance in generating profit from assets compared to the previous year.

Overall, Halozyme Therapeutics Inc's ROA has shown variation over the years, with some periods of high efficiency and profitability followed by fluctuations and subsequent improvements. Monitoring this ratio can help assess the company's ability to generate returns relative to its asset base.